Kynurenic acid and kynurenine aminotransferases in retinal aging and neurodegeneration

Pharmacological Reports

Volumn 63, Issue 6, 2011, Pages 1324-1334

  Rejdak, Robert ^a,b,c   Junemann, Anselm ^d   Grieb, Paweł ^c   Thaler, Sebastian ^a   Schuettauf, Frank ^a   Choraģiewicz, Tomasz ^b   Zarnowski, Tomasz ^b   Turski, Waldemar A ^b,e   Zrenner, Eberhart ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Kynurenic acid; Kynurenine aminotransferase; Neurodegeneration

Indexed keywords

GLUTAMATE RECEPTOR ANTAGONIST; KYNURENIC ACID; KYNURENINE AMINOTRANSFERASE; KYNURENINE AMINOTRANSFERASE I; KYNURENINE AMINOTRANSFERASE II; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; AGING; BRAIN LEVEL; CELL LOSS; CEREBROSPINAL FLUID LEVEL; DISEASE COURSE; ENZYME ACTIVITY; ENZYME SYNTHESIS; EXPERIMENTAL MODEL; GLAUCOMA; IMMUNOREACTIVITY; INTRAOCULAR HYPERTENSION; MUELLER CELL; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; ONTOGENY; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; RETINA DEGENERATION; RETINA GANGLION CELL; REVIEW;

EID: 84857466324     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70697-1     Document Type: Review

References (101)

1. Andine P, Lehmann A, Ellren K, Wennberg E, Kjellmer I, Nielsen T, Hagberg H: The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection. Neurosci Lett, 1988, 90, 208-212.
2. Avendano J, Rodrigues MM, Hackett JJ, Gaskins R: Corpora amylacea of the optic nerve and retina: a form of neuronal degeneration. Invest Ophthalmol Vis Sci, 1980, 19, 550-555. (Pubitemid 11078420)
3. Baran H, Jellinger K, Deecke L: Kynurenine metabolism in Alzheimer's disease. J Neural Transm, 1999, 106, 165-181. (Pubitemid 29137514)
4. Baran H, Okuno E, Kido R, Schwarcz R: Purification and characterization of kynurenine aminotransferase I from human brain. J Neurochem, 1994, 62, 730-738. (Pubitemid 24041344)
5. Beal MF, Swartz KJ, Isacson O: Developmental changes in brain kynurenic acid concentrations. Brain Res Dev Brain Res, 1992, 68, 136-139.
6. Birch PJ, Grossman CJ, Hayes AG: Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol, 1988, 154, 85-87.
7. Botez G, Rami A: Immunoreactivity for Bcl-2 and C-Jun/AP1 in hippocampal corpora amylacea after ischaemia in humans. Neuropathol Appl Neurobiol, 2001, 27, 474-480. (Pubitemid 34264263)
8. Brooks DE, Garcia GA, Dreyer EB, Zurakowski D, Franco-Bourland RE: Vitreous body glutamate concentration in dogs with glaucoma. Am J Vet Res, 1997, 58, 864-867. (Pubitemid 127470799)
9. Carpenedo R, Pittaluga A, Cozzi A, Attucci S, Galli A, Raiteri M, Moroni F: Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur J Neurosci, 2001, 13, 2141-2147. (Pubitemid 32578800)
10. Cavanagh JB: Corpora-amylacea and the family of poly-glucosan diseases. Brain Res Rev, 1999, 29, 265-295.
11. 3H] kynurenine in the developing rat brain in vivo: effect of intrastriatal ibotenate injections. Brain Res Dev Brain Res, 1997, 100, 73-81.
12. Ceresoli-Borroni G, Guidetti P, Schwarcz R: Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats. J Neural Transm, 1999, 106, 229-242. (Pubitemid 29196927)
13. Ceresoli-Borroni G, Schwarcz R: Neonatal asphyxia in rats: acute effects on cerebral kynurenine metabolism. Pediatr Res, 2001, 50, 231-235. (Pubitemid 32701197)
14. Cisse S, Perry G, Lacoste-Royal G, Cabana T, Gauvreau D: Immunochemical identification of ubiquitin and heat-shock proteins in corpora amyleacea from normal aged and Alzheimer's disease brains. Acta Neuropathol, 1993, 85, 233-240. (Pubitemid 23081169)
15. Csillik AE, Okuno E, Csillik B, Knyihar E, Vecsei L: Expression of kynurenine aminotransferase in the subplate of the rat and its possible role in the regulation of programmed cell death. Cereb Cortex, 2002, 12, 1193-1201. (Pubitemid 35191420)
16. Curatalo L, Caccia C, Speciale C, Raimondi L, Cini M, Marconi M, Molinari A, Schwarcz R: Modulation of extracellular kynurenic acid content by excitatory amino acids in primary cultures of rat astrocytes. Adv Exp Med Biol, 1996, 398, 273-276. (Pubitemid 126426240)
17. Dkhissi O, Chanut E, Wasowicz M, Savoldelli M, Nguyen-Legros J, Minvielle F, Versaux-Botteri C: Retinal TUNEL-positive cells and high glutamate levels in vitreous humor of mutant quail with a glaucoma-like disorder. Invest Ophthalmol Vis Sci, 1999, 40, 990-995. (Pubitemid 29153266)
18. Du F, Eid T, Schwarcz R: Neuronal damage after the injection of aminooxyacetic acid into the rat entorhinal cortex: a silver impregnation study. Neuroscience, 1998, 82, 1165-1178. (Pubitemid 27502059)
19. Du F, Schmidt W, Okuno E, Kido R, Kohler C, Schwarcz R: Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus. J Comp Neurol, 1992, 321, 477-487.
20. Dyer MA, Cepko CL: Control of Müller glial cell proliferation and activation following retinal injury. Nat Neurosci, 2000, 3, 873-880.
21. Erhardt S, Olsson SK, Engberg G: Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs, 2009, 23, 91-101.
22. Foster AC, Vezzani A, French ED, Schwarcz R: Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett, 1984, 48, 273-278. (Pubitemid 14054435)
23. Gati I, Leel-Ossy L: Heat shock protein 60 in corpora amylacea. Pathol Oncol Res, 2001, 7, 140-144. (Pubitemid 32729766)
24. Grunder T, Kohler K, Guenther E: Distribution and developmental regulation of AMPA receptor subunit proteins in rat retina. Invest Ophthalmol Vis Sci, 2000, 41, 3600-3606.
25. Grunder T, Kohler K, Kaletta A, Guenther E: The distribution and developmental regulation of NMDA receptor subunit proteins in the outer and inner retina of the rat. J Neurobiol, 2000, 44, 333-342.
26. Guidetti P, Amori L, Sapko MT, Okuno E, Schwarcz R: Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem, 2007, 102, 103-111. (Pubitemid 46906272)
27. Guidetti P, Okuno E, Schwarcz R: Characterization of rat brain kynurenine aminotransferases I and II. J Neurosci Res, 1997, 50, 457-465. (Pubitemid 27488325)
28. Haberecht MF, Redburn DA: High levels of extracellular glutamate are present in retina during neonatal development. Neurochem Res, 1996, 21, 285-291. (Pubitemid 26154457)
29. Hamilton BF, Gould DH: Correlation of morphologic brain lesions with physiologic alterations and blood-brain barrier impairment in 3-nitropropionic acid toxicity in rats. Acta Neuropathol, 1987, 74, 67-74. (Pubitemid 17105420)
30. Han Q, Cai T, Tagle DA, Li J: Thermal stability, pH dependence and inhibition of four murine kynurenine aminotransferases. BMC Biochem, 2010, 11, 19.
31. Han Q, Li J, Li J: pH dependence, substrate specificity and inhibition of human kynurenine aminotransferase I. Eur J Biochem, 2004, 271, 4804-4814. (Pubitemid 40065583)
32. Han Q, Robinson H, Cai T, Tagle DA, Li J: Biochemical and structural properties of mouse kynurenine aminotransferase III. Mol Cell Biol, 2009, 29, 784-793.
33. Han Q, Robinson H, Cai T, Tagle DA, Li J: Biochemical and structural characterization of mouse mitochondrial aspartate aminotransferase, a newly identified kynurenine aminotransferase-IV. Biosci Rep, 2011, 31, 323-332.
34. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX: The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J Neurosci, 2001, 21, 7463-7473. (Pubitemid 32904945)
35. Jenkins BG, Brouillet E, Chen YC, Storey E, Schulz JB, Kirschner P, Beal MF, Rosen BR: Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab, 1996, 16, 450-461. (Pubitemid 26125333)
36. John SW, Smith RS, Savinova OV, Hawes NL, Chung B, Turnbull D, Davisson M et al.: Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. Invest Ophthalmol Vis Sci, 1998, 39, 951-962. (Pubitemid 28196680)
37. Kapoor R, Okuno E, Kido R, Kapoor V: Immunolocalization of kynurenine aminotransferase (KAT) in the rat medulla and spinal cord. Neuroreport, 1997, 8, 3619-3623. (Pubitemid 27497494)
38. Kemp JA, Foster AC, Leeson PD, Priestley T, Tridgett R, Iversen LL, Woodruff GN: 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. Proc Natl Acad Sci USA, 1988, 85, 6547-6550.
39. Knyihar-Csillik E, Okuno E, Vecsei L: Effects of in vivo sodium azide administration on the immunohistochemical localization of kynurenine aminotransferase in the rat brain. Neuroscience, 1999, 94, 269-277. (Pubitemid 29457617)
40. Kocki T, Dolinska M, Dybel A, Urbanska EM, Turski WA, Albrecht J: Regulation of kynurenic acid synthesis in C6 glioma cells. J Neurosci Res, 2002, 68, 622-626. (Pubitemid 34575628)
41. Komuro H, Rakic P: Modulation of neuronal migration by NMDA receptors. Science, 1993, 260, 95-97. (Pubitemid 23122752)
42. Konradsson-Geuken A, Wu HQ, Gash CR, Alexander KS, Campbell A, Sozeri Y, Pellicciari R et al.: Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry. Neuroscience, 2010, 169, 1848-1859.
43. Kubota T, Holbach LM, Naumann GO: Corpora amylacea in glaucomatous and non-glaucomatous optic nerve and retina. Graefes Arch Clin Exp Ophthalmol, 1993, 231, 7-11. (Pubitemid 23023080)
44. Leel-Ossy L: New data on the ultrastructure of the corpus amylaceum (polyglucosan body). Pathol Oncol Res, 2001, 7, 145-150.
45. Lees GJ: Contributory mechanisms in the causation of neurodegenerative disorders. Neuroscience, 1993, 54, 287-322.
46. Lipton SA: Retinal ganglion cells, glaucoma and neuroprotection. Prog Brain Res, 2001, 131, 712-718.
47. Loeffler KU, Edward DP, Tso MO: Tau-2 immunoreactivity of corpora amylacea in the human retina and optic nerve. Invest Ophthalmol Vis Sci, 1993, 34, 2600-2603. (Pubitemid 23206492)
48. Lucas DR, Newhouse JP: The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch Opthalmol, 1957, 58, 193-201.
49. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R: The new '5-HT' hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRY-CATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry, 2011, 35, 702-721.
50. Marty S, Dusart I, Peschanski M: Glial changes following an excitotoxic lesion in the CNS-I. Microglia/macrophages. Neuroscience, 1991, 45, 529-539.
51. Massey SC: Cell types using glutamate as a neurotransmitter in the vertebrate retina. Prog Retinal Res, 1990, 9, 399-425.
52. Moroni F: Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol, 1999, 375, 87-100.
53. Moroni F, Russi P, Lombardi G, Beni M, Carla V: Presence of kynurenic acid in the mammalian brain. J Neurochem, 1988, 51, 177-180.
54. Müller N, Schwarz MJ: A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci, 2008, 258, 2, 97-106. (Pubitemid 351758763)
55. Németh H, Toldi J, Vécsei L: Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J Neural Transm, 2006, 70, Suppl, 285-304.
56. Nozaki K, Beal MF: Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J Cereb Blood Flow Metab, 1992, 12, 400-407.
57. Okuno E, Du F, Ishikawa T, Tsujimoto M, Nakamura M, Schwarcz R, Kido R: Purification and characterization of kynurenine-pyruvate aminotransferase from rat kidney and brain. Brain Res, 1990, 534, 37-44.
58. Okuno E, Nakamura M, Schwarcz R: Two kynurenine aminotransferases in human brain. Brain Res, 1991, 542, 307-312.
59. Olney JW, Wozniak DF, Jevtovic-Todorovic V, Farber NB, Bittigau P, Ikonomidou C: Drug-induced apoptotic neurodegeneration in the developing brain. Brain Pathol, 2002, 12, 488-498. (Pubitemid 35154937)
60. Otori Y, Wie JY, Barnstable CJ: Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest Ophthalmol Vis Sci, 1998, 39, 972-981. (Pubitemid 28196682)
61. Rajda C, Bergquist J, Vecsei L: Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis. J Neural Transm, 2007, 72, Suppl, 323-329.
62. Rejdak R, Kohler K, Kocki T, Shenk Y, Turski WA, Okuno E, Lehaci C et al.: Age-dependent decrease of retinal kynurenate and kynurenine aminotransferases in DBA/2J mice, a model of ocular hypertension. Vision Res, 2004, 44, 655-660. (Pubitemid 38125106)
63. Rejdak R, Rummelt C, Zrenner E, Grieb P, Zarnowski T, Okuno E, Schlotzer-Schrehardt U et al.: Immunohistochemical identification of kynurenine aminotransferases in corpora amylacea in the human retina and optic nerve. Folia Neuropathol, 2007, 45, 66-71. (Pubitemid 47082826)
64. Rejdak R, Shenk Y, Schuettauf F, Turski WA, Okuno E, Zagorski Z, Zrenner E, Kohler K: Expression of kynurenine aminotransferases in the rat retina during development. Vision Res, 2004, 44, 1-7. (Pubitemid 37346236)
65. Rejdak R, Zarnowski T, Turski WA, Kocki T, Zagorski Z, Guenther E, Kohler K, Zrenner E: Changes of kynurenic acid content in the rat and chicken retina during ontogeny. Graefes Arch Clin Exp Ophthalmol, 2002, 240, 687-691. (Pubitemid 36075631)
66. Rejdak R, Zarnowski T, Turski WA, Kocki T, Zagorski Z, Zrenner E, Schuettauf F: Alterations of kynurenic acid content in the retina in response to retinal ganglion cell damage. Vision Res, 2003, 43, 497-503. (Pubitemid 36197793)
67. Rejdak R, Zarnowski T, Turski WA, Okuno E, Kocki T, Zagorski Z, Kohler K et al.: Presence of kynurenic acid and kynurenine aminotransferases in the inner retina. Neuroreport, 2001, 12, 3675-3678. (Pubitemid 33105149)
68. Rejdak R, Zielinska E, Shenk Y, Turski WA, Okuno E, Zarnowski T, Zagorski Z et al.: Ontogenic changes of kynurenine aminotransferase I activity and its expression in the chicken retina. Vision Res, 2003, 43, 1513-1517. (Pubitemid 36629520)
69. Roberts RC, Du F, McCarthy KE, Okuno E, Schwarcz R: Immunocytochemical localization of kynurenine aminotransferase in the rat striatum: a light and electron microscopic study. J Comp Neurol, 1992, 326, 82-90.
70. Saito K, Lackner A, Markey SP, Heyes MP: Cerebral cortex and lung indoleamine-2,3-dioxygenase activity is increased in type-D retrovirus infected macaques. Brain Res, 1991, 540, 353-356.
71. Salvati P, Ukmar G, Dho L, Rosa B, Cini M, Marconi M, Molinari A, Post C: Brain concentrations of kynurenic acid after a systemic neuroprotective dose in the gerbil model of global ischemia. Prog Neuropsychopharmacol Biol Psychiat, 1999, 23, 741-752. (Pubitemid 29268417)
72. Scharfman HE, Goodman JH, Schwarcz R: Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro. Amino Acids, 2000, 19, 283-297.
73. Scheetz AJ, Constantine-Paton M: Modulation of NMDA receptor function: implications for vertebrate neural development. FASEB J, 1994, 8, 745-752. (Pubitemid 24229769)
74. Shepard PD, Joy B, Clerkin L, Schwarcz R: Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology, 2003, 28, 1454-1462. (Pubitemid 41070880)
75. Schuettauf F, Naskar R, Vorwerk CK, Zurakowski D, Dreyer EB: Ganglion cell loss after optic nerve crush mediated through AMPA-kainate and NMDA receptors. Invest Ophthalmol Vis Sci, 2000, 41, 4313-4316.
76. Schuettauf F, Quinto K, Naskar R, Zurakowski D: Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model. Vision Res, 2002, 42, 2333-2337. (Pubitemid 35279167)
77. Schwarcz R, Du F, Schmidt W, Turski WA, Gramsbergen JB, Okuno E, Roberts RC: Kynurenic acid: a potential pathogen in brain disorders. Ann NY Acad Sci, 1992, 648, 140-153.
78. Somohano F, Roberts PJ, Lopez-Colome AM: Maturational changes in retinal excitatory amino acid receptors. Brain Res, 1998, 470, 59-67.
79. Stone TW, Darlington LG: Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov, 2002, 1, 609-620. (Pubitemid 37361524)
80. Sucher NJ, Lipton SA, Dreyer EB: Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res, 1997, 37, 483-3493.
81. Tamburin M, Mostardini M, Benatti L: Kynurenine aminotransferase I (KAT I) isoform gene expression in the rat brain: an in situ hybridization study. Neuroreport, 1999, 10, 61-65. (Pubitemid 29090479)
82. Thaler S, Rejdak R, Dietrich K, Ladewig T, Okuno E, Kocki T, Turski WA et al.: A selective method for transfection of retinal ganglion cells by retrograde transfer of antisense oligonucleotides against kynurenine aminotransferase II. Mol Vis, 2006, 12, 100-107. (Pubitemid 43286429)
83. Turski WA, Gramsbergen J B, Traitler H, Schwarcz R: Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine. J Neurochem, 1989, 52, 1629-1636. (Pubitemid 19109520)
84. Turski WA, Nakamura M, Todd WP, Carpenter BK, Whetsell WO Jr, Schwarcz R: Identification and quantification of kynurenic acid in human brain tissue. Brain Res, 1988, 454, 164-169.
85. Urbanska EM, Chmielewski M, Kocki T, Turski WA: Formation of endogenous glutamatergic receptors antagonist kynurenic acid - differences between cortical and spinal cord slices. Brain Res, 2000, 878, 210-212.
86. Urbanska E, Ikonomidou C, Sieklucka M, Turski WA: Aminooxyacetic acid produces excitotoxic lesions in the rat striatum. Synapse, 1991, 9, 129-135.
87. Urbanska EM, Kocki T, Saran T, Kleinrok Z, Turski WA: Impairment of brain kynurenic acid production by glutamate metabotropic receptor agonists. Neuroreport, 1997, 8, 3501-3505. (Pubitemid 27497472)
88. Urenjak J, Obrenovitch TP: Neuroprotective potency of kynurenic acid against excitotoxicity. Neuroreport, 2000, 27, 1341-1344. (Pubitemid 30262984)
89. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L: Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem, 2006, 281, 22021-22028. (Pubitemid 44181906)
90. Wonodi I, Schwarcz R: Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull, 2010, 36, 211-218.
91. Woodford B, Tso MO: An ultrastructural study of the corpora amylacea of the optic nerve head and retina. Am J Ophthalmol, 1980, 90, 492-502. (Pubitemid 10020972)
92. Wu HQ, Baran H, Ungerstedt U, Schwarcz R: Kynurenic acid in the quinolinate-lesioned rat hippocampus: studies in vitro and in vivo. Eur J Neurosci, 1992, 4, 1264-1270. (Pubitemid 23044621)
93. Wu HQ, Pereira EF, Bruno JP, Pellicciari R, Albuquerque EX, Schwarcz R: The astrocyte-derived α7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci, 2010, 40, 204-210.
94. Vamos E, Pardutz A, Klivenyi P, Toldi J, Vecsei L: The role of kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm, 2009, 116, 1403-1409.
95. Vorwerk CK, Kreutz MR, Dreyer EB, Sabel BA: Systemic L-kynurenine administration partially protects against NMDA, but not kainate-induced degeneration of retinal ganglion cells, and reduces visual discrimination deficits in adults rats. Invest Ophthalmol Vis Sci, 1996, 37, 2382-2392. (Pubitemid 26391276)
96. Yoles E, Schwartz M: Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch Ophthalmol, 1998, 116, 906-910. (Pubitemid 28554781)
97. Yu P, Li Z, Zhang L, Tagle DA, Cai T: Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family. Gene, 2006, 365, 111-118. (Pubitemid 43185231)
98. Zádori D, Klivényi P, Vámos E, Fülöp F, Toldi J, Vécsei L: Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm, 2009, 116, 1403-1409.
99. Zarnowski T, Bialek M, Rejdak R, Zrenner E, Junemann A, Zagorski Z, Kocki T, Turski WA: Kynurenic acid synthesis in bovine retinal slices - effect of glutamate agonists. J Neural Transm, 2006, 113, 1367-1372. (Pubitemid 44435874)
100. Zarnowski T, Rejdak R, Zagorski Z, Junemann AGM, Zrenner E, Kocki T, Urbanska EM, Turski WA: Content of kynurenic acid and activity of kynurenine aminotransferases in mammalian eyes. Ophthalmic Res, 2004, 36, 124-128. (Pubitemid 38437661)
101. Zarnowski T, Rejdak R, Zagorski Z, Kocki T, Kleinrok Z, Turski WA: Evidence for intraocular synthesis of kynurenic acid, a putative endogenous neuroprotectant. Ophthalmic Res, 2001, 33, 107-110. (Pubitemid 32221231)